LOS ANGELES--(BUSINESS WIRE)--
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA) investors concerning the Company and its officers’ possible violations of federal securities laws.
USANA develops, manufactures and sells nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.
On February 7, 2017, USANA disclosed that it will be conducting an internal investigation of its Chinese subsidiary, BabyCare Ltd. (“BabyCare”). Specifically, the Company’s investigation centers upon “compliance with the Foreign Corrupt Practices Act” as well as “BabyCare's expense reimbursement policies.”
On this news, shares of USANA fell over 10% during intraday trading on February 8, 2017.
If you purchased USANA securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170208006307/en/
